10X Genomics, Inc. Stock Price, News & Analysis

10x Genomics, a leader in life sciences, announced its participation in a fireside chat at the BofA Securities 2023 Healthcare Conference on May 10, 2023, at 2:20 p.m. Pacific Time. The event will focus on advancing human health through innovative biological solutions.

Investors can access a live webcast of the chat via the company's website, with an archive available for replay for at least 45 days. 10x Genomics specializes in integrated solutions that include instruments, consumables, and software for biological analysis. The company has a strong presence in top research institutions and pharmaceutical companies, cited in over 4,500 research papers.

10x Genomics (NASDAQ: TXG) announced it will release its first quarter 2023 financial results on May 3, 2023, after market close. A conference call will follow at 1:30 PM PT to discuss the results and future outlook.

The company, a leader in life sciences, provides products for analyzing biological systems, with a significant presence in top global research institutions and pharmaceutical companies. 10x Genomics boasts a portfolio of over 1,750 patents and its products are widely cited in scientific literature.

10x Genomics (Nasdaq: TXG), a leader in life sciences, announced its participation in the 43rd Annual Cowen Healthcare Conference in Boston, Massachusetts, scheduled for March 6, 2023, at 11:10 a.m. Eastern Time. The management team will engage in a fireside chat, which will be accessible via a live webcast on the company’s investors page.

10x Genomics specializes in developing technology to analyze complex biological systems, with a broad patent portfolio and products used by top global research institutions and pharmaceutical companies.

10x Genomics reported Q4 2022 revenue of $156.2 million, up 9% year-over-year, and FY 2022 revenue of $516.4 million, reflecting 5% growth compared to 2021. The increase was driven by strong sales of Chromium X Series instruments, despite a decline in China. New product launches, including the Xenium platform, were highlighted. However, gross margins fell to 76% in Q4 from 81% a year prior, with operating losses widening to $23.1 million. Net loss for Q4 was $17.2 million, slightly improved from $18.4 million in Q4 2021. For 2023, the company forecasts revenue between $580 million and $600 million.

10x Genomics (TXG) announced significant advancements at the 2023 AGBT General Meeting, showcasing its innovative platforms for single-cell analysis and spatial biology.

• Highlighting the scalability of the Chromium Flex platform, demonstrating its capability with data from an 8 million cell experiment.
• New capabilities for Visium CytAssist promise enhanced spatial discovery and a product pipeline including Visium HD.
• The Xenium platform now features a broader menu of customizable panels and the launch of the Xenium Catalyst Program to facilitate researcher access to high-quality data.

These developments reinforce 10x Genomics' leadership in biotechnology.

10x Genomics (TXG) plans to release its financial results for Q4 and full year 2022 on February 15, 2023, after market close. Management will host a conference call at 1:30 PM PT to discuss the results and provide insights on business developments and future outlook. The company's integrated solutions are essential in advancing biological research, with products utilized by top research institutions and pharmaceutical companies. The live webcast will be accessible on their website, with a replay available for at least 45 days.